



News Release

FOR IMMEDIATE RELEASE

Merck Animal Health Announces the Availability of Experimental Autogenous Vaccine for Avian Metapneumovirus Type A through Its Agreement with Cambridge Technologies

The addition of this vaccine marks the first approved offering of inactivated vaccines for the combination of type A and type B in the U.S. to treat metapneumovirus in poultry flocks

RAHWAY, N.J., February, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics has approved the manufacturing and sale of Cambridge Technology's experimental autogenous vaccine in the U.S. for the emerging and deadly avian metapneumovirus type A, impacting broilers, broiler breeders, layers and commercial turkeys and turkey breeders.

In August of 2024, Cambridge Technologies received USDA approval for its experimental autogenous vaccine to address the avian metapneumovirus type B. With this latest approval, it marks the first vaccine in the U.S. to target avian metapneumovirus type A in combination with type B in one bottle.

Merck Animal Health entered into an agreement in early 2024 with Cambridge Technologies, an independent custom vaccine company based in Worthington, Minn., to act as Cambridge's exclusive sales agent for its innovative autogenous poultry vaccines in the U.S. Cambridge Technologies uses cutting-edge molecular diagnostic and manufacturing techniques to develop custom vaccine solutions to help veterinarians and poultry producers manage emerging disease challenges. As part of the agreement, Merck Animal Health provides its expansive customer reach.

"Avian metapneumovirus causes severe respiratory challenges leading to increased mortality rates and drops in egg production in affected flocks," said Ivan Alvarado, D.V.M., innovation discovery livestock technical services for Merck Animal Health. "These novel vaccines developed by Cambridge Technologies are designed to stimulate immunity with precise antigen concentrations. Utilizing an oil in water emulsion, these vaccines have demonstrated low tissue reaction in birds following vaccination, which has been associated with less adverse effects on body weight gain and uniformity. We are proud to serve as Cambridge's exclusive sales agent for these important vaccines."

Cambridge Technologies vaccines are formulated and produced at its USDA-licensed, 37,000-square-foot manufacturing facility featuring state-of-the-art fermentation, virus production, and fill suites.

“Our agreement with Merck Animal Health allows us to combine our diagnostic capabilities with our research and development expertise to deliver custom vaccines that help meet the poultry customer’s specific needs,” said Jon Mahlberg, chief operating officer for Cambridge Technologies. “The Cambridge team is dedicated to delivering cutting-edge vaccines to help address critical needs that enhance flock health and productivity within the poultry industry.”

Contact your Merck Animal Health technical services representative to learn more about custom vaccine products, including the latest vaccines for metapneumovirus type A and type B.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on [LinkedIn](#), [Facebook](#), [X \(formerly Twitter\)](#) and [Instagram](#).

About Cambridge Technologies

Based in Worthington, MN, Cambridge Technologies brings Precision Vaccinology®, our combination of industry-leading diagnostic technology and fully customizable autogenous vaccines, to today’s innovative veterinarians and livestock producers. For more information, visit cambridgetechnologies.com and connect with us on [Facebook](#), [Instagram](#), [LinkedIn](#), and [X \(formerly Twitter\)](#).

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the

candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

###

Media Contact: Kathleen Cuddy
(816) 301-8253
kathleen.cuddy@merck.com